Factors Influencing the Severity of Pneumonitis Associated with Immune Checkpoint Inhibitors: Insights from Clinical, Radiological, and Laboratory Data in Real-World Settings - Takeaways - MDSpire

Factors Influencing the Severity of Pneumonitis Associated with Immune Checkpoint Inhibitors: Insights from Clinical, Radiological, and Laboratory Data in Real-World Settings

  • By

  • Esma Sevil Akkurt

  • Ozlem Duvenci Birben

  • Ilknur Deliktas Onur

  • Duygu Dagli

  • Ozturk Ates

  • Derya Yenibertiz

  • January 28, 2026

  • 0 min

Share

  • 1

    Immune checkpoint inhibitors (ICIs) significantly improve survival in various cancers but can cause serious immune-related adverse events, including pneumonitis.

  • 2

    The incidence of immune checkpoint inhibitor-related pneumonitis (IIP) is reported as 3-5% in clinical trials, with higher rates in real-world settings, especially in lung cancer patients.

  • 3

    IIP can present with symptoms ranging from mild cough to severe respiratory failure, necessitating early recognition and timely treatment to prevent adverse outcomes.

  • 4

    Diagnosis of IIP requires integration of clinical evaluation, thoracic CT findings, and bronchoscopy to rule out other causes like infection or tumor progression.

  • 5

    This study aims to evaluate factors influencing IIP severity and management approaches in real-world oncology practice, addressing gaps in current clinical data.

Original Source(s)

Factors Influencing the Severity of Pneumonitis Associated with Immune Checkpoint Inhibitors: Insights from Clinical, Radiological, and Laboratory Data in Real-World Settings

  • by Esma Sevil Akkurt, Ozlem Duvenci Birben, Ilknur Deliktas Onur, Duygu Dagli, Ozturk Ates, Derya Yenibertiz

  • January 28, 2026

Related Content

FEBAIR microsurgical principles in meningiomas and recurrence: a long-term follow-up series

High-grade astrocytoma with piloid features: a case report of comprehensive management

Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation